Relationship Between Residual Renal Function and Serum Fibroblast Growth Factor 23 in Patients on Peritoneal Dialysis

Shunsuke Yamada, Kazuhiko Tsuruya, Masatomo Taniguchi, Hisako Yoshida, Masanori Tokumoto, Shoko Hasegawa, Shigeru Tanaka, Masahiro Eriguchi, Toshiaki Nakano, Takanari Kitazono

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Fibroblast growth factor 23 (FGF23) levels in dialysis patients are influenced by various factors, including phosphorus load. However, the clinical parameters that determine serum FGF23 levels in patients on peritoneal dialysis (PD) remain unclear. The aim of the present study was to examine the effects of clinical factors, on serum FGF23 levels, with an emphasis on residual renal function (RRF). This cross-sectional study included 56 outpatients undergoing PD therapy. Urine volume ≥100mL/day or renal creatinine (Cr) clearance was used as a surrogate marker for RRF. Clinical characteristics were compared between patients with and without RRF. Linear regression analysis was conducted with serum FGF23 level as the dependent variable and renal Cr clearance as the main independent variable. The median and interquartile range of serum FGF23 levels were 5970 (1451-11688) pg/mL. Patients with RRF showed higher urinary and total phosphate eliminations, and lower serum FGF23 and phosphate levels than patients without RRF. Multivariate linear regression analysis showed that the renal Cr clearance and serum phosphate and dialysis history were negatively associated with serum FGF23 levels, even after adjusting for potential confounders including peritoneal Cr clearance. Further, the predictabilities of serum FGF23 were comparable among renal Cr clearance, Kt/V for urea, and renal phosphate clearance. RRF determined by renal Cr clearance or residual urine volume is an independent negative determinant of serum FGF23 levels in PD patients.

Original languageEnglish
Pages (from-to)383-390
Number of pages8
JournalTherapeutic Apheresis and Dialysis
Volume18
Issue number5
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Peritoneal Dialysis
Kidney
Serum
Creatinine
Phosphates
fibroblast growth factor 23
Dialysis
Linear Models
Regression Analysis
Urine
Residual Volume
Phosphorus
Urea
Outpatients
Cross-Sectional Studies
Biomarkers

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Relationship Between Residual Renal Function and Serum Fibroblast Growth Factor 23 in Patients on Peritoneal Dialysis. / Yamada, Shunsuke; Tsuruya, Kazuhiko; Taniguchi, Masatomo; Yoshida, Hisako; Tokumoto, Masanori; Hasegawa, Shoko; Tanaka, Shigeru; Eriguchi, Masahiro; Nakano, Toshiaki; Kitazono, Takanari.

In: Therapeutic Apheresis and Dialysis, Vol. 18, No. 5, 01.01.2014, p. 383-390.

Research output: Contribution to journalArticle

Yamada, Shunsuke ; Tsuruya, Kazuhiko ; Taniguchi, Masatomo ; Yoshida, Hisako ; Tokumoto, Masanori ; Hasegawa, Shoko ; Tanaka, Shigeru ; Eriguchi, Masahiro ; Nakano, Toshiaki ; Kitazono, Takanari. / Relationship Between Residual Renal Function and Serum Fibroblast Growth Factor 23 in Patients on Peritoneal Dialysis. In: Therapeutic Apheresis and Dialysis. 2014 ; Vol. 18, No. 5. pp. 383-390.
@article{90c832833d334445a2f907f4f80d706a,
title = "Relationship Between Residual Renal Function and Serum Fibroblast Growth Factor 23 in Patients on Peritoneal Dialysis",
abstract = "Fibroblast growth factor 23 (FGF23) levels in dialysis patients are influenced by various factors, including phosphorus load. However, the clinical parameters that determine serum FGF23 levels in patients on peritoneal dialysis (PD) remain unclear. The aim of the present study was to examine the effects of clinical factors, on serum FGF23 levels, with an emphasis on residual renal function (RRF). This cross-sectional study included 56 outpatients undergoing PD therapy. Urine volume ≥100mL/day or renal creatinine (Cr) clearance was used as a surrogate marker for RRF. Clinical characteristics were compared between patients with and without RRF. Linear regression analysis was conducted with serum FGF23 level as the dependent variable and renal Cr clearance as the main independent variable. The median and interquartile range of serum FGF23 levels were 5970 (1451-11688) pg/mL. Patients with RRF showed higher urinary and total phosphate eliminations, and lower serum FGF23 and phosphate levels than patients without RRF. Multivariate linear regression analysis showed that the renal Cr clearance and serum phosphate and dialysis history were negatively associated with serum FGF23 levels, even after adjusting for potential confounders including peritoneal Cr clearance. Further, the predictabilities of serum FGF23 were comparable among renal Cr clearance, Kt/V for urea, and renal phosphate clearance. RRF determined by renal Cr clearance or residual urine volume is an independent negative determinant of serum FGF23 levels in PD patients.",
author = "Shunsuke Yamada and Kazuhiko Tsuruya and Masatomo Taniguchi and Hisako Yoshida and Masanori Tokumoto and Shoko Hasegawa and Shigeru Tanaka and Masahiro Eriguchi and Toshiaki Nakano and Takanari Kitazono",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/1744-9987.12170",
language = "English",
volume = "18",
pages = "383--390",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Relationship Between Residual Renal Function and Serum Fibroblast Growth Factor 23 in Patients on Peritoneal Dialysis

AU - Yamada, Shunsuke

AU - Tsuruya, Kazuhiko

AU - Taniguchi, Masatomo

AU - Yoshida, Hisako

AU - Tokumoto, Masanori

AU - Hasegawa, Shoko

AU - Tanaka, Shigeru

AU - Eriguchi, Masahiro

AU - Nakano, Toshiaki

AU - Kitazono, Takanari

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Fibroblast growth factor 23 (FGF23) levels in dialysis patients are influenced by various factors, including phosphorus load. However, the clinical parameters that determine serum FGF23 levels in patients on peritoneal dialysis (PD) remain unclear. The aim of the present study was to examine the effects of clinical factors, on serum FGF23 levels, with an emphasis on residual renal function (RRF). This cross-sectional study included 56 outpatients undergoing PD therapy. Urine volume ≥100mL/day or renal creatinine (Cr) clearance was used as a surrogate marker for RRF. Clinical characteristics were compared between patients with and without RRF. Linear regression analysis was conducted with serum FGF23 level as the dependent variable and renal Cr clearance as the main independent variable. The median and interquartile range of serum FGF23 levels were 5970 (1451-11688) pg/mL. Patients with RRF showed higher urinary and total phosphate eliminations, and lower serum FGF23 and phosphate levels than patients without RRF. Multivariate linear regression analysis showed that the renal Cr clearance and serum phosphate and dialysis history were negatively associated with serum FGF23 levels, even after adjusting for potential confounders including peritoneal Cr clearance. Further, the predictabilities of serum FGF23 were comparable among renal Cr clearance, Kt/V for urea, and renal phosphate clearance. RRF determined by renal Cr clearance or residual urine volume is an independent negative determinant of serum FGF23 levels in PD patients.

AB - Fibroblast growth factor 23 (FGF23) levels in dialysis patients are influenced by various factors, including phosphorus load. However, the clinical parameters that determine serum FGF23 levels in patients on peritoneal dialysis (PD) remain unclear. The aim of the present study was to examine the effects of clinical factors, on serum FGF23 levels, with an emphasis on residual renal function (RRF). This cross-sectional study included 56 outpatients undergoing PD therapy. Urine volume ≥100mL/day or renal creatinine (Cr) clearance was used as a surrogate marker for RRF. Clinical characteristics were compared between patients with and without RRF. Linear regression analysis was conducted with serum FGF23 level as the dependent variable and renal Cr clearance as the main independent variable. The median and interquartile range of serum FGF23 levels were 5970 (1451-11688) pg/mL. Patients with RRF showed higher urinary and total phosphate eliminations, and lower serum FGF23 and phosphate levels than patients without RRF. Multivariate linear regression analysis showed that the renal Cr clearance and serum phosphate and dialysis history were negatively associated with serum FGF23 levels, even after adjusting for potential confounders including peritoneal Cr clearance. Further, the predictabilities of serum FGF23 were comparable among renal Cr clearance, Kt/V for urea, and renal phosphate clearance. RRF determined by renal Cr clearance or residual urine volume is an independent negative determinant of serum FGF23 levels in PD patients.

UR - http://www.scopus.com/inward/record.url?scp=84909979990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909979990&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.12170

DO - 10.1111/1744-9987.12170

M3 - Article

C2 - 24674095

AN - SCOPUS:84909979990

VL - 18

SP - 383

EP - 390

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 5

ER -